Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of LQT-1213 in Healthy Adults
NCT05759962Phase 1Completed
- Sponsor
- Thryv Therapeutics Inc.
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LQT-1213 in long QT syndrome (LQTS) (6 arms), sponsored by Thryv Therapeutics Inc. Primary endpoint: Number of Participants with Adverse Events at Day 16. Started Sep 2022; status: completed.
02
Drugs
LQT-1213
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT05759962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759962.